Alnylam Pharma Reports Q2 2026 Earnings with Strong Revenue Growth
Alnylam Pharmaceuticals (ALNY) reported second-quarter earnings for 2026, highlighting significant revenue growth driven by the uptake of AMVUTTRA in ATTR cardiomyopathy. Total net product revenues reached $1.2 billion, a 74% increase year-over-year. The TTR franchise exceeded $1 billion in quarterly revenue for the first time with total TTR net product revenues at $1.03 billion. The company revised its guidance downward due to normalization of second-line demand growth but raised collaboration and royalty revenue forecasts based on strong Leqvio performance. Alnylam also announced an expanded clinical trial, TRITON-CM, now enrolling 1,750 patients in preparation for the nucresiran launch by 2030. The company's cash position stood at $3.3 billion as of June 30, 2026, and it reported high patient adherence rates to AMVUTTRA exceeding 90%. Despite some downward revisions in guidance, Alnylam remains optimistic about long-term growth with a delayed generic entry for tafamidis until mid-2031.
